Skip to menu Skip to content Skip to footer

2021

Journal Article

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Lewis, Katharine L., Chin, Collin K., Manos, Kate, Casey, John, Hamad, Nada, Crawford, Julie, Ho, Shir-Jing, Issa, Samar, Grigg, Andrew, Wood, Peter, Gandhi, Maher K., Do, Bryan, Nastoupil, Loretta, Hawkes, Eliza A. and Cheah, Chan Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192 (6) bjh.16946, 1049-1053. doi: 10.1111/bjh.16946

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

2021

Journal Article

Targeted treatment of follicular lymphoma

Nath, Karthik and Gandhi, Maher K. (2021). Targeted treatment of follicular lymphoma. Journal of Personalized Medicine, 11 (2) 152, 1-22. doi: 10.3390/jpm11020152

Targeted treatment of follicular lymphoma

2021

Journal Article

Tumor microenvironment of follicular lymphoma

Nath, Karthik, Tsang, Hennes and Gandhi, Maher K. (2021). Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 5, 1-19. doi: 10.21037/aol-20-55

Tumor microenvironment of follicular lymphoma

2021

Book Chapter

Host genetic mutations and expression analyses in PTLD

Lees, Charlotte and Gandhi, Maher K. (2021). Host genetic mutations and expression analyses in PTLD. Post-transplant lymphoproliferative disorders. (pp. 39-50) edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe. Cham, Switzerland: Springer . doi: 10.1007/978-3-030-65403-0_4

Host genetic mutations and expression analyses in PTLD

2021

Journal Article

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma

2020

Journal Article

Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment

Kobayashi, Takumi, Lam, Pui Yeng, Jiang, Hui, Bednarska, Karolina, Gloury, Renee Elyse, Murigneux, Valentine, Tay, Joshua, Jacquelot, Nicolas, Li, Rui, Tuong, Zewen Kelvin, Leggatt, Graham, Gandhi, Maher K., Hill, Michelle M, Belz, Gabrielle T., Ngo, Shyuan, Kallies, Axel and Mattarollo, Stephen R. (2020). Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 136 (26), 3004-3017. doi: 10.1182/blood.2020005602

Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment

2020

Conference Publication

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

2020

Conference Publication

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

Tobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590

A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma

2020

Journal Article

DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?

Hertzberg, Mark, Joske, David J. L. and Gandhi, Maher K. (2020). DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?. Journal of Clinical Oncology, 38 (31), 3722-3723. doi: 10.1200/jco.20.01850

DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?

2020

Journal Article

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma

Gunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma

2020

Journal Article

Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?

Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?. American Journal of Hematology, 95 (12) ajh.26016, 1454-1456. doi: 10.1002/ajh.26016

Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?

2020

Journal Article

Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

Bararia, Deepak, Hildebrand, Johannes A., Stolz, Sebastian, Haebe, Sarah, Alig, Stefan, Trevisani, Christopher P., Osorio-Barrios, Francisco, Bartoschek, Michael D., Mentz, Michael, Pastore, Alessandro, Gaitzsch, Erik, Heide, Michael, Jurinovic, Vindi, Rautter, Katharina, Gunawardana, Jay, Sabdia, Muhammed B., Szczepanowski, Monika, Richter, Julia, Klapper, Wolfram, Louissaint, Abner, Ludwig, Christina, Bultmann, Sebastian, Leonhardt, Heinrich, Eustermann, Sebastian, Hopfner, Karl-Peter, Hiddemann, Wolfgang, von Bergwelt-Baildon, Michael, Steidl, Christian, Kridel, Robert ... Weigert, Oliver (2020). Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Reports, 31 (5) 107522, 107522. doi: 10.1016/j.celrep.2020.107522

Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

2020

Journal Article

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark and Gandhi, Maher K. (2020). LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 4 (7), 1367-1377. doi: 10.1182/bloodadvances.2019001390

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

2020

Journal Article

Reply to M. Sorigue

Tobin, Joshua W.D., Keane, Colm, Gunawardana, Jay and Gandhi, Maher K. (2020). Reply to M. Sorigue. Journal of Clinical Oncology, 38 (6), 648-649. doi: 10.1200/JCO.19.02935

Reply to M. Sorigue

2020

Journal Article

Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

Nakamura, Kyohei, Casey, Mika, Oey, Harald, Vari, Frank, Stagg, John, Gandhi, Maher K. and Smyth, Mark J. (2020). Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 34 (10), 2708-2721. doi: 10.1038/s41375-020-0811-3

Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody

2019

Conference Publication

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

Nath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

2019

Journal Article

EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2

Cristino, Alexandre S., Nourse, Jamie, West, Rachael A., Sabdia, Muhammed Bilal, Law, Soi C., Gunawardana, Jay, Vari, Frank, Mujaj, Sally, Thillaiyampalam, Gayathri, Snell, Cameron, Gough, Madeline, Keane, Colm and Gandhi, Maher K. (2019). EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2. Blood, 134 (25), 2261-2270. doi: 10.1182/blood.2019000889

EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2

2019

Journal Article

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

2019

Journal Article

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

2019

Journal Article

Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration

Tobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365

Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration